Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 60.0 %

NASDAQ EGRX opened at $0.80 on Tuesday. The stock has a 50-day simple moving average of $2.51 and a two-hundred day simple moving average of $3.87. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.40.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $59,000. Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at about $145,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at about $65,000. Perceptive Advisors LLC purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at about $971,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at about $60,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.